Key positives include a distinctive scientific focus on allosteric modulation, strong liquidity with low financial leverage, and a pipeline that offers multiple potential value drivers across neurology and addiction medicine. The Neurosterix transaction has both extended the cash runway and preserved upside in a broad discovery platform, while partnerships with larger companies validate the technology and share development risk. Cost discipline has also clearly improved the company’s financial resilience compared with a few years ago.

Major risks stem from persistent operating losses, a very small and declining revenue base, and the inherently binary nature of clinical development. The failure of one partnered program already underlines how quickly value can shift when trials disappoint. Reduced internal R&D spending may slow the creation of new assets and increase reliance on external partners, while ongoing losses mean that, over time, the company is likely to depend on further external capital or deal activity. Accumulated losses and volatility in equity levels reflect this fragile economic position.

Addex appears to be in a transition phase, moving from a discovery‑heavy model toward a leaner, asset‑ and partnership‑focused biotech with leveraged exposure to a broader external pipeline. Financially, the balance sheet and cash trends now look more stable than they did during the earlier contraction, but the business remains fundamentally pre‑commercial and loss‑making. The medium‑term trajectory will hinge on clinical and partnership outcomes: progress in GABAB programs, clarity on dipraglurant’s path, and value creation at Neurosterix will be central in determining whether the current strategy can eventually translate scientific strengths into a more durable economic model.